In:
International Journal of Cancer, Wiley, Vol. 136, No. 6 ( 2015-03-15), p. 1434-1444
Abstract:
What's new? As cells acquire cancerous phenotypes, they experience significant changes in metabolism. A key regulator of those changes is AMP‐activated protein kinase (AMPK), which serves a complex role in cancer. Here, the multikinase inhibitor sorafenib was found as an activator of AMPK, via involvement of LKB1 and CAMKK2. When sorafenib was combined with the AMPK activator metformin, synergistic growth inhibition was observed in NSCLC cells in vitro and in vivo . The combination was found to improve disease control rate in a phase II clinical trial of patients with KRAS mutant advanced non‐small cell lung cancer (NSCLC).
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
